AstraZeneca biologics arm MedImmune and WuXi AppTec have formed a joint venture (JV) to develop and commercialize MEDI5117, a new biologic for autoimmune and inflammatory diseases for China.
As part of the JV, MedImmune will provide technical and development support while WuXi AppTec will provide local regulatory, manufacturing, pre-clinical and clinical trial support.